8 completed, 3 unknown, 2 not yet recruiting, 2 terminated. 17 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 8, Unknown 3, Not yet recruiting 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 6, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Urinary Calculi: new trials by email Literature Review of Urinary Calculi trials Research Report on Urinary Calculi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) YOLT-203 - Primary Hyperoxaluria Type 1, PH1 | Phase 1 | Recruiting | YolTech Therapeutics Co., Ltd | 9 | 2026-08-01 | 2026-08-20 |
| Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention Potassium Citrate Extended Release Oral Tablet - Kidney Calculi | Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 20 | 2026-07-01 | 2026-02-05 |
| Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones Potassium Citrate, Sodium Bicarbonate - Kidney Stones, Urolithiasis, Hypocitraturia, Nephrolithiasis | Phase 1 / Phase 2 | Not yet recruiting | University of California, Los Angeles | 30 | 2026-02-01 | 2026-02-12 |
| A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria BMN 255, Placebo - Hyperoxaluria, Nonalcoholic Fatty Liver Disease | Phase 1 | Withdrawn | BioMarin Pharmaceutical | 2023-09-26 | 2024-06-11 | |
| Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria FB-001, Placebo - Healthy, Enteric Hyperoxaluria | Phase 1 | Unknown | Federation Bio Inc. | 48 | 2022-11-16 | 2023-01-25 |
| Silodosin in Management of Lower Ureteral Stones Silodosin - Stone, Kidney | Phase 1 / Phase 2 | Completed | Syrian Private University | 100 | 2022-10-20 | 2024-04-24 |
| Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects NOV-001, NB1000S, NB2000P - Healthy Volunteers, Enteric Hyperoxaluria | Phase 1 / Phase 2 | Terminated | Novome Biotechnologies Inc | 153 | 2021-06-02 | 2023-05-17 |
| Pramipexole and Morphine for Renal Colic Pramipexole, Morphine, Placebo oral tablet - Renal Colic | Phase 1 / Phase 2 | Completed | East Carolina University | 19 | 2019-10-28 | 2023-03-08 |
| Treatment of Renal Stones With Frankincense (Luban) AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid), Potassium Sodium Hydrogen Citrate - Renal Stones | Phase 1 / Phase 2 | Unknown | Sultan Qaboos University | 100 | 2019-09-01 | 2019-04-29 |
| A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) DCR-PH1, Placebo - Primary Hyperoxaluria Type 1 | Phase 1 | Terminated | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 41 | 2016-05-13 | 2024-07-11 |
| Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study Tolvaptan, Placebo - Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate | Phase 1 | Completed | Mayo Clinic | 20 | 2014-03-01 | 2016-03-30 |
| Use of Lapis Judaicus to Dissolve Kidney Stones Lapis Judaicus, Placebo - Kidney Calculi | Phase 1 / Phase 2 | Completed | Shiraz University of Medical Sciences | 60 | 2011-01-01 | 2013-12-02 |
| Lime Powder Regimen in Healthy Volunteers Lime powder regime - Kidney Stone, Oxidative Stress | Phase 1 | Unknown | Chulalongkorn University | 15 | 2010-12-01 | 2011-01-10 |
| Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones OMS201, Vehicle - Urinary Calculi, Urinary Stones | Phase 1 / Phase 2 | Completed | Omeros Corporation | 18 | 2009-03-01 | 2012-10-12 |
| Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones OMS201, Vehicle - Urinary Calculi, Urinary Stones | Phase 1 | Completed | Omeros Corporation | 11 | 2007-12-01 | 2010-04-30 |
| Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones Cystone, Sugar Pill (Placebo) - Cystinuria, Nephrolithiasis, Calcium Oxalate | Phase 1 / Phase 2 | Completed | Mayo Clinic | 20 | 2006-04-01 | 2016-02-04 |
| Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Oxadrop, Agri-King Synbiotic (AKSB), Placebo - Nephrolithiasis, Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 40 | 2006-02-01 | 2012-05-31 |
Kidney Calculi (16) · Hyperoxaluria (5) · Nephrolithiasis (5) · Calculi (4) · Nephrolithiasis, Calcium Oxalate (2) · Primary hyperoxaluria type 1 (2) · Urolithiasis (2) · Agnosia (1) · Crohn Disease (1) · Cystinuria (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1) · Hyperoxaluria, Primary (1) · Metabolic Diseases (1)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Pathological Conditions, Anatomical (17) · Pathological Conditions, Signs and Symptoms (17) · Urogenital Diseases (17) · Kidney Diseases (16) · Urologic Diseases (16) · Urolithiasis (15) · Calculi (13) · Nephrolithiasis (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Digestive System Diseases (3) · Genetic Diseases, Inborn (2)
Citrates (1) · Frankincense (1) · Morphine (1) · Potassium Citrate (1) · Powders (1) · Pramipexole (1) · Sodium Bicarbonate (1) · Sugars (1) · Tablets (1) · Tolvaptan (1) · cystone (1) · potassium-magnesium citrate (1) · silodosin (1)
Mayo Clinic (3) · Omeros Corporation (2) · BioMarin Pharmaceutical (1) · Chulalongkorn University (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · East Carolina University (1) · Federation Bio Inc. (1) · Novome Biotechnologies Inc (1) · Shiraz University of Medical Sciences (1) · Sultan Qaboos University (1) · Syrian Private University (1) · University of California, Los Angeles (1) · University of Texas Southwestern Medical Center (1) · YolTech Therapeutics Co., Ltd (1)
United States (10) · Canada (2) · China (1) · Germany (1) · Iceland (1) · Iran (1) · Netherlands (1) · Oman (1) · Syria (1) · Thailand (1)
Andreas Grauer, MD (1) · Jamshid Roozbeh, MD (1) · John C Lieske, MD (1) · John Lieske, MD (1) · Kori Brewer, PhD (1) · Kymora B Scotland, MD, PhD (1) · Lachy McLean, MB ChB, PhD (1) · Poonsin Poungpairoj, BSc (1) · Scott Houston (1) · Stephen B. Erickson, M.D. (1)
PMID 20736987, PMID 21161651, PMID 21419606, PMID 39411383
P50DK083007 (2), R21AT002534 (1), UL1RR024150 (1)